 |
|
|
| |
SAFETY OF RIBAVIRIN-CONTAINING REGIMENS OF ABT-450/r, ABT-333, AND ABT-267 FOR THE TREATMENT OF HCV GENOTYPE 1 INFECTION AND EFFICACY IN SUBJECTS WITH RIBAVIRIN DOSE REDUCTIONS
|
| |
| |
Reported by Jules Levin
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention
Kuala Lumpur, Malaysia · 02 July 2013
Daniel E. Cohen, Wangang Xie, Lois Larsen, Christal Marincic, Mary Knauss-Townsend, Amit Khatri, Thomas Podsadecki, Barry Bernstein
AbbVie Inc., North Chicago, IL, United States
|
| |
|
|
|
|
|
